Review



scc25 cells  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    ATCC scc25 cells
    Analgesic effects of Rimegepant in OSCC-associated pain demonstrated via the unilateral tongue orthotopic transplantation model. A Construction of the unilateral tongue orthotopic transplantation model and drug injection with mechanical threshold measurement protocol. B Following tumor transplantation, the differences in mechanical sensitivity between the transplanted ( n = 14) and non-transplanted ( n = 10) sides were compared using unpaired two-tailed Student’s t test. C Changes in sensitivity 1 h after Rimegepant (50 mg/kg), Rimegepant (10 mg/kg) and Carprofen treatment were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). D Changes in sensitivity following Rimegepant (50 mg/kg) and Tramadol treatment at 1 h were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). E The 4-day trends of facial mechanical sensitivities 24 h after Rimegepant (50 mg/kg) and Tramadol treatment. ( n = 6–8/group). F Changes in sensitivity 1 h after Tramadol, Carprofen treatment and local lingual injection of Rimegepant (10 mg/kg) in CAL27 and <t>SCC25</t> xenograft models were performed using one-way ANOVA( n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns P > 0.05
    Scc25 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1324 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc25+cells/pmc13173713-52-4-10?v=ATCC
    Average 97 stars, based on 1324 article reviews
    scc25 cells - by Bioz Stars, 2026-06
    97/100 stars

    Images

    1) Product Images from "Targeting CGRP signaling alleviates cancer-associated pain in oral squamous cell carcinoma"

    Article Title: Targeting CGRP signaling alleviates cancer-associated pain in oral squamous cell carcinoma

    Journal: BMC Oral Health

    doi: 10.1186/s12903-026-08444-x

    Analgesic effects of Rimegepant in OSCC-associated pain demonstrated via the unilateral tongue orthotopic transplantation model. A Construction of the unilateral tongue orthotopic transplantation model and drug injection with mechanical threshold measurement protocol. B Following tumor transplantation, the differences in mechanical sensitivity between the transplanted ( n = 14) and non-transplanted ( n = 10) sides were compared using unpaired two-tailed Student’s t test. C Changes in sensitivity 1 h after Rimegepant (50 mg/kg), Rimegepant (10 mg/kg) and Carprofen treatment were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). D Changes in sensitivity following Rimegepant (50 mg/kg) and Tramadol treatment at 1 h were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). E The 4-day trends of facial mechanical sensitivities 24 h after Rimegepant (50 mg/kg) and Tramadol treatment. ( n = 6–8/group). F Changes in sensitivity 1 h after Tramadol, Carprofen treatment and local lingual injection of Rimegepant (10 mg/kg) in CAL27 and SCC25 xenograft models were performed using one-way ANOVA( n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns P > 0.05
    Figure Legend Snippet: Analgesic effects of Rimegepant in OSCC-associated pain demonstrated via the unilateral tongue orthotopic transplantation model. A Construction of the unilateral tongue orthotopic transplantation model and drug injection with mechanical threshold measurement protocol. B Following tumor transplantation, the differences in mechanical sensitivity between the transplanted ( n = 14) and non-transplanted ( n = 10) sides were compared using unpaired two-tailed Student’s t test. C Changes in sensitivity 1 h after Rimegepant (50 mg/kg), Rimegepant (10 mg/kg) and Carprofen treatment were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). D Changes in sensitivity following Rimegepant (50 mg/kg) and Tramadol treatment at 1 h were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). E The 4-day trends of facial mechanical sensitivities 24 h after Rimegepant (50 mg/kg) and Tramadol treatment. ( n = 6–8/group). F Changes in sensitivity 1 h after Tramadol, Carprofen treatment and local lingual injection of Rimegepant (10 mg/kg) in CAL27 and SCC25 xenograft models were performed using one-way ANOVA( n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns P > 0.05

    Techniques Used: Transplantation Assay, Injection, Two Tailed Test



    Similar Products

    97
    ATCC scc25 cells
    Analgesic effects of Rimegepant in OSCC-associated pain demonstrated via the unilateral tongue orthotopic transplantation model. A Construction of the unilateral tongue orthotopic transplantation model and drug injection with mechanical threshold measurement protocol. B Following tumor transplantation, the differences in mechanical sensitivity between the transplanted ( n = 14) and non-transplanted ( n = 10) sides were compared using unpaired two-tailed Student’s t test. C Changes in sensitivity 1 h after Rimegepant (50 mg/kg), Rimegepant (10 mg/kg) and Carprofen treatment were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). D Changes in sensitivity following Rimegepant (50 mg/kg) and Tramadol treatment at 1 h were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). E The 4-day trends of facial mechanical sensitivities 24 h after Rimegepant (50 mg/kg) and Tramadol treatment. ( n = 6–8/group). F Changes in sensitivity 1 h after Tramadol, Carprofen treatment and local lingual injection of Rimegepant (10 mg/kg) in CAL27 and <t>SCC25</t> xenograft models were performed using one-way ANOVA( n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns P > 0.05
    Scc25 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc25+cells/pmc13173713-52-4-10?v=ATCC
    Average 97 stars, based on 1 article reviews
    scc25 cells - by Bioz Stars, 2026-06
    97/100 stars
      Buy from Supplier

    96
    ATCC homo sapiens tongue squamous cell carcinoma cell line scc25
    Analgesic effects of Rimegepant in OSCC-associated pain demonstrated via the unilateral tongue orthotopic transplantation model. A Construction of the unilateral tongue orthotopic transplantation model and drug injection with mechanical threshold measurement protocol. B Following tumor transplantation, the differences in mechanical sensitivity between the transplanted ( n = 14) and non-transplanted ( n = 10) sides were compared using unpaired two-tailed Student’s t test. C Changes in sensitivity 1 h after Rimegepant (50 mg/kg), Rimegepant (10 mg/kg) and Carprofen treatment were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). D Changes in sensitivity following Rimegepant (50 mg/kg) and Tramadol treatment at 1 h were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). E The 4-day trends of facial mechanical sensitivities 24 h after Rimegepant (50 mg/kg) and Tramadol treatment. ( n = 6–8/group). F Changes in sensitivity 1 h after Tramadol, Carprofen treatment and local lingual injection of Rimegepant (10 mg/kg) in CAL27 and <t>SCC25</t> xenograft models were performed using one-way ANOVA( n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns P > 0.05
    Homo Sapiens Tongue Squamous Cell Carcinoma Cell Line Scc25, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc25+cells/10__1016_slash_j__phyplu__2025__100941-81-7-20?v=ATCC
    Average 96 stars, based on 1 article reviews
    homo sapiens tongue squamous cell carcinoma cell line scc25 - by Bioz Stars, 2026-06
    96/100 stars
      Buy from Supplier

    86
    Procell Inc human oscc cell lines scc25
    Analgesic effects of Rimegepant in OSCC-associated pain demonstrated via the unilateral tongue orthotopic transplantation model. A Construction of the unilateral tongue orthotopic transplantation model and drug injection with mechanical threshold measurement protocol. B Following tumor transplantation, the differences in mechanical sensitivity between the transplanted ( n = 14) and non-transplanted ( n = 10) sides were compared using unpaired two-tailed Student’s t test. C Changes in sensitivity 1 h after Rimegepant (50 mg/kg), Rimegepant (10 mg/kg) and Carprofen treatment were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). D Changes in sensitivity following Rimegepant (50 mg/kg) and Tramadol treatment at 1 h were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). E The 4-day trends of facial mechanical sensitivities 24 h after Rimegepant (50 mg/kg) and Tramadol treatment. ( n = 6–8/group). F Changes in sensitivity 1 h after Tramadol, Carprofen treatment and local lingual injection of Rimegepant (10 mg/kg) in CAL27 and <t>SCC25</t> xenograft models were performed using one-way ANOVA( n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns P > 0.05
    Human Oscc Cell Lines Scc25, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc25+cells/pm42286153-186-1-11?v=Procell+Inc
    Average 86 stars, based on 1 article reviews
    human oscc cell lines scc25 - by Bioz Stars, 2026-06
    86/100 stars
      Buy from Supplier

    97
    ATCC oscc cell lines scc25
    Analgesic effects of Rimegepant in OSCC-associated pain demonstrated via the unilateral tongue orthotopic transplantation model. A Construction of the unilateral tongue orthotopic transplantation model and drug injection with mechanical threshold measurement protocol. B Following tumor transplantation, the differences in mechanical sensitivity between the transplanted ( n = 14) and non-transplanted ( n = 10) sides were compared using unpaired two-tailed Student’s t test. C Changes in sensitivity 1 h after Rimegepant (50 mg/kg), Rimegepant (10 mg/kg) and Carprofen treatment were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). D Changes in sensitivity following Rimegepant (50 mg/kg) and Tramadol treatment at 1 h were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). E The 4-day trends of facial mechanical sensitivities 24 h after Rimegepant (50 mg/kg) and Tramadol treatment. ( n = 6–8/group). F Changes in sensitivity 1 h after Tramadol, Carprofen treatment and local lingual injection of Rimegepant (10 mg/kg) in CAL27 and <t>SCC25</t> xenograft models were performed using one-way ANOVA( n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns P > 0.05
    Oscc Cell Lines Scc25, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc25+cells/pm41896711-56-12-34?v=ATCC
    Average 97 stars, based on 1 article reviews
    oscc cell lines scc25 - by Bioz Stars, 2026-06
    97/100 stars
      Buy from Supplier

    97
    ATCC pr es s human hnscc cell lines scc25
    Analgesic effects of Rimegepant in OSCC-associated pain demonstrated via the unilateral tongue orthotopic transplantation model. A Construction of the unilateral tongue orthotopic transplantation model and drug injection with mechanical threshold measurement protocol. B Following tumor transplantation, the differences in mechanical sensitivity between the transplanted ( n = 14) and non-transplanted ( n = 10) sides were compared using unpaired two-tailed Student’s t test. C Changes in sensitivity 1 h after Rimegepant (50 mg/kg), Rimegepant (10 mg/kg) and Carprofen treatment were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). D Changes in sensitivity following Rimegepant (50 mg/kg) and Tramadol treatment at 1 h were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). E The 4-day trends of facial mechanical sensitivities 24 h after Rimegepant (50 mg/kg) and Tramadol treatment. ( n = 6–8/group). F Changes in sensitivity 1 h after Tramadol, Carprofen treatment and local lingual injection of Rimegepant (10 mg/kg) in CAL27 and <t>SCC25</t> xenograft models were performed using one-way ANOVA( n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns P > 0.05
    Pr Es S Human Hnscc Cell Lines Scc25, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc25+cells/pm41765937-100-8-25?v=ATCC
    Average 97 stars, based on 1 article reviews
    pr es s human hnscc cell lines scc25 - by Bioz Stars, 2026-06
    97/100 stars
      Buy from Supplier

    97
    ATCC human hnscc cell line scc25
    LIS1 increases the migration, invasion, and PNI capability of HNSCC cells. ( A ) Wound healing assay of LIS1 overexpression or LIS1 knockdown in <t>SCC25</t> cells. ( B ) Transwell assay of LIS1 overexpression or LIS1 knockdown in SCC25 cells. ( C ) Representative images of the in vitro PNI model for LIS1 overexpression or LIS1 knockdown in SCC25 cells. ( D ) Microfluidic chip pattern diagram and representative images of LIS1 overexpression or LIS1 knockdown in SCC25 cells co-cultured with SCs in the microfluidic chip. Data are represented as mean ± SEM, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001
    Human Hnscc Cell Line Scc25, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc25+cells/pmc13059471-65-0-14?v=ATCC
    Average 97 stars, based on 1 article reviews
    human hnscc cell line scc25 - by Bioz Stars, 2026-06
    97/100 stars
      Buy from Supplier

    97
    ATCC scc25 tongue hnscc cell lines
    Interleukin-32 (IL-32) induces EMT in HNSCC cells, and neutralisation of IL-32 attenuates EMT-associated morphology and proteins. Phase-contrast images of FaDu and <t>SCC25</t> cells cultured for 24 h in control medium, CAF-conditioned medium (CAF-CM), recombinant IL-32 (rIL-32, 50 ng mL −1 ), or CAF-CM plus an IL-32-neutralising antibody (IL-32 Ab). CAF-CM and rIL-32 induce elongated, spindle-like morphology with microspike-like protrusions (red arrows), whereas addition of IL-32 Ab markedly suppresses these features. Scale bars = 200 μm (A). Immunoblots showing EMT-related protein changes in FaDu and SCC25 cells with or without rIL-32. rIL-32 increases IL-32, Snail, Twist, Vimentin and Fibronectin, while reducing the epithelial marker E-cadherin. β-Tubulin serves as the loading control (B). Western-blot comparison of CAF-CM versus CAF-CM + IL-32 Ab. Neutralising IL-32 diminishes IL-32, Snail and Twist, restores E-cadherin, and lowers Vimentin and Fibronectin levels (C). Together these data confirm that IL-32 is sufficient to trigger EMT in head and neck squamous cell carcinoma cells.
    Scc25 Tongue Hnscc Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc25+cells/pmc12826013-28-3-12?v=ATCC
    Average 97 stars, based on 1 article reviews
    scc25 tongue hnscc cell lines - by Bioz Stars, 2026-06
    97/100 stars
      Buy from Supplier

    97
    ATCC human oral squamous cell carcinoma oscc cell lines scc25
    Interleukin-32 (IL-32) induces EMT in HNSCC cells, and neutralisation of IL-32 attenuates EMT-associated morphology and proteins. Phase-contrast images of FaDu and <t>SCC25</t> cells cultured for 24 h in control medium, CAF-conditioned medium (CAF-CM), recombinant IL-32 (rIL-32, 50 ng mL −1 ), or CAF-CM plus an IL-32-neutralising antibody (IL-32 Ab). CAF-CM and rIL-32 induce elongated, spindle-like morphology with microspike-like protrusions (red arrows), whereas addition of IL-32 Ab markedly suppresses these features. Scale bars = 200 μm (A). Immunoblots showing EMT-related protein changes in FaDu and SCC25 cells with or without rIL-32. rIL-32 increases IL-32, Snail, Twist, Vimentin and Fibronectin, while reducing the epithelial marker E-cadherin. β-Tubulin serves as the loading control (B). Western-blot comparison of CAF-CM versus CAF-CM + IL-32 Ab. Neutralising IL-32 diminishes IL-32, Snail and Twist, restores E-cadherin, and lowers Vimentin and Fibronectin levels (C). Together these data confirm that IL-32 is sufficient to trigger EMT in head and neck squamous cell carcinoma cells.
    Human Oral Squamous Cell Carcinoma Oscc Cell Lines Scc25, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc25+cells/pm41039015-52-4-21?v=ATCC
    Average 97 stars, based on 1 article reviews
    human oral squamous cell carcinoma oscc cell lines scc25 - by Bioz Stars, 2026-06
    97/100 stars
      Buy from Supplier

    Image Search Results


    Analgesic effects of Rimegepant in OSCC-associated pain demonstrated via the unilateral tongue orthotopic transplantation model. A Construction of the unilateral tongue orthotopic transplantation model and drug injection with mechanical threshold measurement protocol. B Following tumor transplantation, the differences in mechanical sensitivity between the transplanted ( n = 14) and non-transplanted ( n = 10) sides were compared using unpaired two-tailed Student’s t test. C Changes in sensitivity 1 h after Rimegepant (50 mg/kg), Rimegepant (10 mg/kg) and Carprofen treatment were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). D Changes in sensitivity following Rimegepant (50 mg/kg) and Tramadol treatment at 1 h were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). E The 4-day trends of facial mechanical sensitivities 24 h after Rimegepant (50 mg/kg) and Tramadol treatment. ( n = 6–8/group). F Changes in sensitivity 1 h after Tramadol, Carprofen treatment and local lingual injection of Rimegepant (10 mg/kg) in CAL27 and SCC25 xenograft models were performed using one-way ANOVA( n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns P > 0.05

    Journal: BMC Oral Health

    Article Title: Targeting CGRP signaling alleviates cancer-associated pain in oral squamous cell carcinoma

    doi: 10.1186/s12903-026-08444-x

    Figure Lengend Snippet: Analgesic effects of Rimegepant in OSCC-associated pain demonstrated via the unilateral tongue orthotopic transplantation model. A Construction of the unilateral tongue orthotopic transplantation model and drug injection with mechanical threshold measurement protocol. B Following tumor transplantation, the differences in mechanical sensitivity between the transplanted ( n = 14) and non-transplanted ( n = 10) sides were compared using unpaired two-tailed Student’s t test. C Changes in sensitivity 1 h after Rimegepant (50 mg/kg), Rimegepant (10 mg/kg) and Carprofen treatment were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). D Changes in sensitivity following Rimegepant (50 mg/kg) and Tramadol treatment at 1 h were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). E The 4-day trends of facial mechanical sensitivities 24 h after Rimegepant (50 mg/kg) and Tramadol treatment. ( n = 6–8/group). F Changes in sensitivity 1 h after Tramadol, Carprofen treatment and local lingual injection of Rimegepant (10 mg/kg) in CAL27 and SCC25 xenograft models were performed using one-way ANOVA( n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns P > 0.05

    Article Snippet: Human OSCC CAL27 and SCC25 cells were purchased from the American Type Culture Collection (USA).

    Techniques: Transplantation Assay, Injection, Two Tailed Test

    LIS1 increases the migration, invasion, and PNI capability of HNSCC cells. ( A ) Wound healing assay of LIS1 overexpression or LIS1 knockdown in SCC25 cells. ( B ) Transwell assay of LIS1 overexpression or LIS1 knockdown in SCC25 cells. ( C ) Representative images of the in vitro PNI model for LIS1 overexpression or LIS1 knockdown in SCC25 cells. ( D ) Microfluidic chip pattern diagram and representative images of LIS1 overexpression or LIS1 knockdown in SCC25 cells co-cultured with SCs in the microfluidic chip. Data are represented as mean ± SEM, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

    Journal: Cancer Cell International

    Article Title: LIS1 mediated Schwann cell reprogramming enhances perineural invasion by activating the serine/NMDAR/AKT signaling pathway in head and neck squamous carcinoma

    doi: 10.1186/s12935-026-04243-0

    Figure Lengend Snippet: LIS1 increases the migration, invasion, and PNI capability of HNSCC cells. ( A ) Wound healing assay of LIS1 overexpression or LIS1 knockdown in SCC25 cells. ( B ) Transwell assay of LIS1 overexpression or LIS1 knockdown in SCC25 cells. ( C ) Representative images of the in vitro PNI model for LIS1 overexpression or LIS1 knockdown in SCC25 cells. ( D ) Microfluidic chip pattern diagram and representative images of LIS1 overexpression or LIS1 knockdown in SCC25 cells co-cultured with SCs in the microfluidic chip. Data are represented as mean ± SEM, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

    Article Snippet: Human HNSCC cell line (SCC25) and human Schwann cells (sNF96.2) were acquired from the American Type Culture Collection (ATCC, Manassas, VA, USA) in 2023.

    Techniques: Migration, Wound Healing Assay, Over Expression, Knockdown, Transwell Assay, In Vitro, Cell Culture

    LIS1 overexpression of HNSCC cells increases Schwann cells activity. ( A ) The pattern diagram of HNSCC cells co-cultured with SCs. ( B ) Transwell assay of sNF96.2 cells co-cultured with SCC25 cells. ( C ) The mRNA expression of PNI-related factors (BDNF, GDNF, NGF, MMP2, and MMP9) in sNF96.2 cells co-cultured with SCC25 cells were analyzed by RT-qPCR. ( D ) IF double staining was performed to detect the expression of S100 and GFAP in the sNF96.2 cells co-cultured with SCC25 cells. Data are represented as mean ± SEM, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

    Journal: Cancer Cell International

    Article Title: LIS1 mediated Schwann cell reprogramming enhances perineural invasion by activating the serine/NMDAR/AKT signaling pathway in head and neck squamous carcinoma

    doi: 10.1186/s12935-026-04243-0

    Figure Lengend Snippet: LIS1 overexpression of HNSCC cells increases Schwann cells activity. ( A ) The pattern diagram of HNSCC cells co-cultured with SCs. ( B ) Transwell assay of sNF96.2 cells co-cultured with SCC25 cells. ( C ) The mRNA expression of PNI-related factors (BDNF, GDNF, NGF, MMP2, and MMP9) in sNF96.2 cells co-cultured with SCC25 cells were analyzed by RT-qPCR. ( D ) IF double staining was performed to detect the expression of S100 and GFAP in the sNF96.2 cells co-cultured with SCC25 cells. Data are represented as mean ± SEM, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

    Article Snippet: Human HNSCC cell line (SCC25) and human Schwann cells (sNF96.2) were acquired from the American Type Culture Collection (ATCC, Manassas, VA, USA) in 2023.

    Techniques: Over Expression, Activity Assay, Cell Culture, Transwell Assay, Expressing, Quantitative RT-PCR, Double Staining

    LIS1 overexpression activates the serine signaling pathway to promote the PNI in HNSCC cells. ( A ) The mRNA expression of PHGDH, PSAT1, and PSPH in SCC25 cells were analyzed by RT-qPCR. ( B ) Analysis of the relative intracellular serine levels in SCC25 cells. ( C ) The protein level of PHGDH, PSAT1, and PSPH in SCC25 cells were analyzed by WB. ( D ) Migration and invasion assay of shLIS1 group after exogenous serine stimulation of SCC25 cells and quantitative analysis. ( E ) Representative images of the in vitro PNI model for shLIS1 group after exogenous serine stimulation of SCC25 cells and the analysis of neural invasion index. ( F ) Representative images of the microfluidic chip for shLIS1 group after exogenous serine stimulation of SCC25 cells and analysis of migration distance. Data are represented as mean ± SEM, ** P < 0.01, *** P < 0.001, **** P < 0.0001

    Journal: Cancer Cell International

    Article Title: LIS1 mediated Schwann cell reprogramming enhances perineural invasion by activating the serine/NMDAR/AKT signaling pathway in head and neck squamous carcinoma

    doi: 10.1186/s12935-026-04243-0

    Figure Lengend Snippet: LIS1 overexpression activates the serine signaling pathway to promote the PNI in HNSCC cells. ( A ) The mRNA expression of PHGDH, PSAT1, and PSPH in SCC25 cells were analyzed by RT-qPCR. ( B ) Analysis of the relative intracellular serine levels in SCC25 cells. ( C ) The protein level of PHGDH, PSAT1, and PSPH in SCC25 cells were analyzed by WB. ( D ) Migration and invasion assay of shLIS1 group after exogenous serine stimulation of SCC25 cells and quantitative analysis. ( E ) Representative images of the in vitro PNI model for shLIS1 group after exogenous serine stimulation of SCC25 cells and the analysis of neural invasion index. ( F ) Representative images of the microfluidic chip for shLIS1 group after exogenous serine stimulation of SCC25 cells and analysis of migration distance. Data are represented as mean ± SEM, ** P < 0.01, *** P < 0.001, **** P < 0.0001

    Article Snippet: Human HNSCC cell line (SCC25) and human Schwann cells (sNF96.2) were acquired from the American Type Culture Collection (ATCC, Manassas, VA, USA) in 2023.

    Techniques: Over Expression, Expressing, Quantitative RT-PCR, Migration, Invasion Assay, In Vitro

    Interleukin-32 (IL-32) induces EMT in HNSCC cells, and neutralisation of IL-32 attenuates EMT-associated morphology and proteins. Phase-contrast images of FaDu and SCC25 cells cultured for 24 h in control medium, CAF-conditioned medium (CAF-CM), recombinant IL-32 (rIL-32, 50 ng mL −1 ), or CAF-CM plus an IL-32-neutralising antibody (IL-32 Ab). CAF-CM and rIL-32 induce elongated, spindle-like morphology with microspike-like protrusions (red arrows), whereas addition of IL-32 Ab markedly suppresses these features. Scale bars = 200 μm (A). Immunoblots showing EMT-related protein changes in FaDu and SCC25 cells with or without rIL-32. rIL-32 increases IL-32, Snail, Twist, Vimentin and Fibronectin, while reducing the epithelial marker E-cadherin. β-Tubulin serves as the loading control (B). Western-blot comparison of CAF-CM versus CAF-CM + IL-32 Ab. Neutralising IL-32 diminishes IL-32, Snail and Twist, restores E-cadherin, and lowers Vimentin and Fibronectin levels (C). Together these data confirm that IL-32 is sufficient to trigger EMT in head and neck squamous cell carcinoma cells.

    Journal: Journal of Dental Sciences

    Article Title: Tumor microenvironment-derived IL-32 promotes aggressive phenotypes and stem cell traits in head and neck squamous cell carcinoma

    doi: 10.1016/j.jds.2025.10.010

    Figure Lengend Snippet: Interleukin-32 (IL-32) induces EMT in HNSCC cells, and neutralisation of IL-32 attenuates EMT-associated morphology and proteins. Phase-contrast images of FaDu and SCC25 cells cultured for 24 h in control medium, CAF-conditioned medium (CAF-CM), recombinant IL-32 (rIL-32, 50 ng mL −1 ), or CAF-CM plus an IL-32-neutralising antibody (IL-32 Ab). CAF-CM and rIL-32 induce elongated, spindle-like morphology with microspike-like protrusions (red arrows), whereas addition of IL-32 Ab markedly suppresses these features. Scale bars = 200 μm (A). Immunoblots showing EMT-related protein changes in FaDu and SCC25 cells with or without rIL-32. rIL-32 increases IL-32, Snail, Twist, Vimentin and Fibronectin, while reducing the epithelial marker E-cadherin. β-Tubulin serves as the loading control (B). Western-blot comparison of CAF-CM versus CAF-CM + IL-32 Ab. Neutralising IL-32 diminishes IL-32, Snail and Twist, restores E-cadherin, and lowers Vimentin and Fibronectin levels (C). Together these data confirm that IL-32 is sufficient to trigger EMT in head and neck squamous cell carcinoma cells.

    Article Snippet: FaDu (hypopharyngeal) and SCC25 (tongue) HNSCC cell lines were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA).

    Techniques: Cell Culture, Control, Recombinant, Western Blot, Marker, Comparison

    CAF-derived interleukin-32 (IL-32) promotes migration and invasion of HNSCC cells, and IL-32 neutralisation reverses these effects. Migration assay. Crystal-violet-stained FaDu and SCC25 cells that traversed 8 μm Transwell filters after 24 h in control medium, CAF-CM or recombinant IL-32 (50 ng mL −1 ) or CAF-CM plus an IL-32-neutralising antibody (CAF-CM + IL-32 Ab). CAF-CM and rIL-32 markedly increased motility, whereas addition of IL-32 Ab reduced migration towards near-baseline levels. Right, quantification as fold change relative to control (mean ± SD, n = 3; one-way ANOVA with Tukey's post-hoc; ∗∗ P < 0.01 vs control). Scale bars = 1 mm (A). Invasion assay. Cells were seeded on Matrigel-coated inserts and allowed to invade for 48 h under the same conditions. Quantification (right) indicates a significant 1.5- to 2-fold increase in invading cells with CAF-CM or rIL-32, while IL-32 Ab blunted this effect (mean ± SD, n = 3; ∗∗ P < 0.01 vs control). Scale bars = 1 mm (B). Three-dimensional organotypic model. Haematoxylin-and-eosin-stained sections of collagen/Matrigel gels populated with normal fibroblasts (NF) or CAFs and overlaid with FaDu or SCC25 cells. After 14 d, CAF co-culture produced deeper epithelial invasion (arrows) compared with NF controls, whereas inclusion of IL-32 Ab with CAF-CM largely abolished invasion. Scale bars = 1 mm (C). Collectively, these data confirm that CAF-secreted IL-32 potentiates HNSCC cell migration and invasion in both 2-D and physiologically relevant 3-D settings.

    Journal: Journal of Dental Sciences

    Article Title: Tumor microenvironment-derived IL-32 promotes aggressive phenotypes and stem cell traits in head and neck squamous cell carcinoma

    doi: 10.1016/j.jds.2025.10.010

    Figure Lengend Snippet: CAF-derived interleukin-32 (IL-32) promotes migration and invasion of HNSCC cells, and IL-32 neutralisation reverses these effects. Migration assay. Crystal-violet-stained FaDu and SCC25 cells that traversed 8 μm Transwell filters after 24 h in control medium, CAF-CM or recombinant IL-32 (50 ng mL −1 ) or CAF-CM plus an IL-32-neutralising antibody (CAF-CM + IL-32 Ab). CAF-CM and rIL-32 markedly increased motility, whereas addition of IL-32 Ab reduced migration towards near-baseline levels. Right, quantification as fold change relative to control (mean ± SD, n = 3; one-way ANOVA with Tukey's post-hoc; ∗∗ P < 0.01 vs control). Scale bars = 1 mm (A). Invasion assay. Cells were seeded on Matrigel-coated inserts and allowed to invade for 48 h under the same conditions. Quantification (right) indicates a significant 1.5- to 2-fold increase in invading cells with CAF-CM or rIL-32, while IL-32 Ab blunted this effect (mean ± SD, n = 3; ∗∗ P < 0.01 vs control). Scale bars = 1 mm (B). Three-dimensional organotypic model. Haematoxylin-and-eosin-stained sections of collagen/Matrigel gels populated with normal fibroblasts (NF) or CAFs and overlaid with FaDu or SCC25 cells. After 14 d, CAF co-culture produced deeper epithelial invasion (arrows) compared with NF controls, whereas inclusion of IL-32 Ab with CAF-CM largely abolished invasion. Scale bars = 1 mm (C). Collectively, these data confirm that CAF-secreted IL-32 potentiates HNSCC cell migration and invasion in both 2-D and physiologically relevant 3-D settings.

    Article Snippet: FaDu (hypopharyngeal) and SCC25 (tongue) HNSCC cell lines were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA).

    Techniques: Derivative Assay, Migration, Staining, Control, Recombinant, Invasion Assay, Co-Culture Assay, Produced

    Interleukin-32 (IL-32) enhances cancer-stem-cell (CSC) properties in HNSCC cells. Representative phase-contrast micrographs of tumourspheres formed by FaDu and SCC25 cells cultured for 10 days in serum-free medium with or without recombinant IL-32 (rIL-32, 50 ng mL −1 ). rIL-32 treatment markedly increases both sphere size and number. Scale bars = 1 mm (A). Immunoblots showing stemness-associated transcription factors Oct-4, SOX2 and NANOG in control (WT) and rIL-32-treated cells. β-Tubulin serves as a loading control; rIL-32 elevates all three markers, indicating augmented stemness (B). Flow-cytometric analysis of surface CSC markers. Histograms illustrate CD24, CD44 and CD133 expression profiles for WT and rIL-32-treated FaDu (left) and SCC25 (right) populations; M2 gates (purple) represent positive cells. Bar graphs (bottom) depict mean ± SD fold change in CD44 + /CD24 + and CD133 + subsets (n = 3). ∗ P < 0.05; ∗∗∗ P < 0.001 versus control (two-tailed t-test). These data demonstrate that IL-32 not only drives EMT and invasion but also potentiates CSC traits in head and neck squamous cell carcinoma cells (C).

    Journal: Journal of Dental Sciences

    Article Title: Tumor microenvironment-derived IL-32 promotes aggressive phenotypes and stem cell traits in head and neck squamous cell carcinoma

    doi: 10.1016/j.jds.2025.10.010

    Figure Lengend Snippet: Interleukin-32 (IL-32) enhances cancer-stem-cell (CSC) properties in HNSCC cells. Representative phase-contrast micrographs of tumourspheres formed by FaDu and SCC25 cells cultured for 10 days in serum-free medium with or without recombinant IL-32 (rIL-32, 50 ng mL −1 ). rIL-32 treatment markedly increases both sphere size and number. Scale bars = 1 mm (A). Immunoblots showing stemness-associated transcription factors Oct-4, SOX2 and NANOG in control (WT) and rIL-32-treated cells. β-Tubulin serves as a loading control; rIL-32 elevates all three markers, indicating augmented stemness (B). Flow-cytometric analysis of surface CSC markers. Histograms illustrate CD24, CD44 and CD133 expression profiles for WT and rIL-32-treated FaDu (left) and SCC25 (right) populations; M2 gates (purple) represent positive cells. Bar graphs (bottom) depict mean ± SD fold change in CD44 + /CD24 + and CD133 + subsets (n = 3). ∗ P < 0.05; ∗∗∗ P < 0.001 versus control (two-tailed t-test). These data demonstrate that IL-32 not only drives EMT and invasion but also potentiates CSC traits in head and neck squamous cell carcinoma cells (C).

    Article Snippet: FaDu (hypopharyngeal) and SCC25 (tongue) HNSCC cell lines were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA).

    Techniques: Cell Culture, Recombinant, Western Blot, Control, Expressing, Two Tailed Test